Monrol Announces Investment to Expand its n.c.a. Lu-177 Production Capacity
11.9.2023 19:15:00 EEST | Business Wire | Press release
Eczacıbaşı Monrol Nuclear Products Co. (Monrol), one of the world's leading radiopharmaceutical producers, has decided to invest 35 million Euros to increase its production capacity for non-carrier-added Lutetium-177 (n.c.a. Lu-177) in response to growing global demand for this product.
Monrol, which manufactures radiopharmaceuticals meeting high quality standards at its production facilities, plans to increase its current n.c.a. Lu-177 production capacity through the expansion of existing production lines at the Monrol Gebze facility in Turkey as well as the establishment of a new production facility at the Gebze campus. The expansion project will come into operation gradually and reach full capacity by 2026.
N.c.a. Lu-177 is the radionuclide that forms the basis of targeted radioligand therapy(*), widely used today in the treatment of prostate cancer and neuroendocrine tumors and expected to be used soon to treat other cancers as well.
“Prostate cancer is the most common type of cancer in men after lung cancer, with its incidence increasing rapidly around the world. By 2040, 2.3 million new cases of prostate cancer are predicted annually worldwide. The production capacity increase at our Gebze facility in Turkey, which will comply fully with EU and US quality standards, will meet the increasing global demand for n.c.a. Lu-177. In fact, we aim to make the Gebze production facility a “center of excellence” for the production of theranostic products,” commented Aydin Kucuk, General Manager of Monrol.
(*) Targeted radioligand therapy, is an innovative approach to cancer treatment. Multiple clinical trials are investigating the effects of this treatment approach on various types of cancers across the world.
ENDS
About Monrol
Headquartered in Istanbul, Monrol is a nuclear medicine company leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals, Monrol distributes its world-class radiopharmaceutical products portfolio in global markets. As both a CMO and CDMO, Monrol provides early development support to customers and offers fully integrated services for nimble, lean, virtual companies taking new product concepts into clinical trials, demonstrating proof of concept, and going into first-in-human studies. Monrol is committed to transform and improve patient journey in cancer treatment through a portfolio of radiopharmaceutical products that it distributes to more than 60 countries around the globe. To learn more, visit www.monrol.com and LinkedIn.
About n.c.a. Lutetium-177
Lutetium-177 n.c.a. is a radioisotope of choice for targeted radionuclide therapy. Lu-177 n.c.a. enables treatment options that have the potential today to improve treatment outcomes for certain cancer patients and may soon offer improved treatment options for others, thanks to ongoing clinical development. The unique properties of Lu-177 n.c.a. make it a desirable radioisotope for peptide receptor radionuclide therapy (PRRT) used to treat certain cancers like Neuro Endocrine Tumors (NET) and Prostate cancer. Monrol n.c.a. Lutetium-177 DMF has been listed by the FDA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230911648623/en/
Contact information
For further information please contact:
Monrol
Aydın Küçük
General Manager
monrol@monrol.com
Media Enquiries
Alkim Aydın
Marketing Manager
alkim.aydin@monrol.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global Adds Depth to Tax and Global Mobility Capabilities in Germany30.6.2026 16:30:00 EEST | Press release
Andersen Global strengthens its presence through a Collaboration Agreement with Lohr and Company (L+C), a senior-led tax advisory platform, providing practical, responsive solutions in tax compliance, cross-border tax, global mobility, and transfer pricing. Headquartered in Germany with a presence in Austria, L+C advises large multinationals and family-owned companies, family offices, foundations, and high-net-worth individuals. The firm, founded in 2001, specializes in areas such as global mobility, M&A, international tax law, country-by-country reporting, and transfer pricing, including Pillar 2 reporting. Additionally, L+C supports clients with trusts and foundations, tax compliance, payroll and financial accounting, and private financial advisory services. “Collaborating with Andersen Global represents an important step in expanding our international capabilities and strengthening the value we provide to clients navigating increasingly complex cross-border matters,” said Jörg-Andre
90% of IT Leaders See Gaps in AI Threat Readiness, Lenovo Brings Single Point of Accountability to Cyber Resiliency30.6.2026 16:00:00 EEST | Press release
As organizations accelerate AI adoption and digital workplace transformation, many are finding that cyber resilience is undermined not by a lack of security tools, but by growing operational complexity and threat sophistication. According to recent research, 90% of IT leaders acknowledge gaps in their ability to defend against AI-driven threats. While security investments continue to grow, many organizations face a different challenge: fragmented accountability. Security operations remain highly distributed and siloed, making it increasingly difficult to coordinate response efforts, maintain end-to-end business continuity, and recover quickly when incidents occur. To help organizations address this challenge, Lenovo is expanding its global Security Services portfolio with a revamped cyber resiliency framework and end-to-end security offerings designed to provide a single point of accountability, help organizations reduce security complexity, cut system downtime by up to 50%, and lower
SC Therapeutics Initiates REACH2 Trial for Refractory Chronic Cough30.6.2026 16:00:00 EEST | Press release
SC Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies that deactivate mechano-sensitive ion channels (MSCs) to treat respiratory and cardiovascular disease, today reports initiation of the REACH2 trial. The study will evaluate the Company's lead product candidate in patients with refractory chronic cough (RCC) – a debilitating condition for which no disease-modifying treatment options currently exist. The trial will be run in three major cough centers across the UK. A Novel, Disease-Modifying Mechanism of Action SC0032, SC Therapeutics' most advanced product candidate, is a proprietary therapeutic aerosol composed entirely of ions endogenous to human airways. Unlike current symptomatic investigational drugs – including P2X3 receptor antagonists and neurokinin-1 (NK1) receptor antagonists that seek to dampen neural hypersensitivity through receptor blockade – SC0032’s approach directly addresses the upstream inflammatory drivers of chronic cough. By acting to
Tacton Launches Portfolio Performance Intelligence to Help Manufacturers Understand Why Products Win30.6.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) solutions for manufacturers of complex products, today announced the launch of Portfolio Performance Intelligence, a new analytics capability designed to help manufacturers understand why products win, where margin is created or lost, and which decisions consistently drive successful business outcomes. Manufacturers don't lack data. They lack the context needed to understand why products perform the way they do and why customers choose them. ERP systems show what was sold, CRM platforms track opportunities, and BI tools visualize trends. But when manufacturers try to understand which customer requirements drive demand, which configurations consistently win, or why margins vary across products, regions or segments, the answers are often unclear. That's because the most important layer of insight–the connection between customer needs, configuration decisions and deal outcomes–only exists within CPQ. “As product complexity increases
Riskified Study: As AI Drives a Summer Travel Boom, Clunky Security and Scam Fears Threaten Merchant Conversions30.6.2026 15:30:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released findings from global survey conducted ahead of the 2026 Summer Travel season, exploring consumer travel behavior, booking experiences, and trust in digital and AI-enabled travel tools. The survey, conducted among more than 4,000 consumers across the United States, United Kingdom, China, Japan, Mexico, Brazil, and Colombia, shows strong demand for travel heading into the summer season, alongside continued adoption of digital and AI tools in trip planning. Key findings from the Riskified 2026 Summer Travel Survey include: 81% of consumers use digital platforms for travel planning, with 26% already relying on AI like ChatGPT or Gemini. Leisure remains the dominant purpose of travel at 63%, followed by visiting friends and family (25%), going to live events (7%), and business travel (5%). 47% cite payment security and 39% cite fake or invalid tickets as top concerns when buying tickets online.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom